Filtros de búsqueda

Lista de obras de Bernard Escudier

A 10-year clinical experience with intermittent hormonal therapy for prostate cancer

artículo científico publicado en 2003

A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies

artículo científico publicado en 2015

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

artículo científico publicado en 2011

A germline mutation in PBRM1 predisposes to renal cell carcinoma

artículo científico publicado en 2015

A new workflow for proteomic analysis of urinary exosomes and assessment in cystinuria patients

artículo científico publicado en 2014

A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma

artículo científico publicado en 2009

A phase II study of irinotecan in patients with advanced renal cell carcinoma

artículo científico publicado en 2003

A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases

artículo científico publicado en 2013

A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer

artículo científico publicado en 2014

Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen.

artículo científico publicado en 2012

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

artículo científico publicado en 2016

Advanced renal cell carcinoma: current and emerging management strategies

artículo científico publicado en 2007

Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes

artículo científico publicado en 2015

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

artículo científico publicado en 2008

Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients

artículo científico publicado en 2004

Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer

artículo científico publicado en 2017

Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial

artículo científico publicado en 2013

Assessment of Early Tumour Shrinkage: Ready for Integration in the Treatment Strategy for Metastatic Renal Cell Carcinoma?

artículo científico publicado en 2016

Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study

artículo científico publicado en 2010

Axitinib for the management of metastatic renal cell carcinoma

artículo científico publicado en 2011

Axitinib in metastatic renal cell carcinoma

artículo científico

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

artículo científico publicado en 2013

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

artículo científico publicado en 2007

Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma

scientific article published on October 2008

Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

artículo científico publicado en 2010

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner

artículo científico publicado en 2005

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

artículo científico publicado en 2017

Cabozantinib for the treatment of renal cell carcinoma

artículo científico publicado en 2016

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

artículo científico publicado en 2015

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.

artículo científico publicado en 2018

Chemo-immunotherapy in RCC: the end of a story

artículo científico publicado en 2010

Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.

artículo científico publicado en 2008

Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis

artículo científico publicado en 2016

Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma

artículo científico publicado en 2014

Combination Interleukin-2 and Doxorubicin in Advanced Adult Solid Tumors: Circumvention of Doxorubicin Resistance in Soft-Tissue Sarcoma?

artículo científico publicado en 1999

Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review

artículo científico publicado en 2011

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.

artículo científico publicado en 2012

Considerations for the design of future clinical trials in metastatic renal cell carcinoma

artículo científico publicado en 2013

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial

artículo científico publicado en 2017

Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage

artículo científico publicado en 2020

Current and future strategies in nonclear-cell metastatic renal cell carcinoma

artículo científico

Cutaneous side-effects of kinase inhibitors and blocking antibodies

artículo científico publicado en 2005

Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.

artículo científico publicado en 2016

Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha

artículo científico publicado en 2009

Dermatologic symptoms associated with the multikinase inhibitor sorafenib

artículo científico publicado en 2008

Development and validation of a real-time PCR assay for the detection and quantitation of p53 recombinant adenovirus in clinical samples from patients treated with Ad5CMV-p53 (INGN 201) ⬇️

artículo científico publicado el 1 de diciembre de 2003

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

artículo científico publicado en 2010

Does a reasonable treatment approach beyond second-line exist?

artículo científico

Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors

artículo científico publicado en 2018

Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors

artículo científico publicado en 2016

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

artículo científico publicado en 2008

Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.

artículo científico publicado en 2015

Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma

artículo científico publicado en 2006

Emerging tyrosine kinase inhibitors for the treatment of renal cancer

artículo científico

Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interaction

artículo científico publicado en 2002

Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71].

artículo científico publicado en 2018

Erratum: Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

artículo científico publicado en 2015

Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy

artículo científico publicado en 2017

Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma

artículo científico publicado en 2014

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells

artículo científico publicado en 2004

Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection

artículo científico

Experience with sorafenib and the elderly patient

artículo científico publicado en 2009

Feasibility and oncological outcomes of laparoscopic treatment for local relapse of renal cell carcinoma

artículo científico publicado en 2013

Feasibility of nephron-sparing surgery in giant oncocytoma

artículo científico publicado en 2014

Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy

artículo científico publicado en 2014

Genomic heterogeneity of translocation renal cell carcinoma

artículo científico publicado en 2013

Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma

artículo científico

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

artículo científico publicado en 2017

Gynecologic bleeding revealing vaginal metastasis of renal cell carcinoma

artículo científico publicado en 2013

HIF-2α/ITPR1 axis: A new saboteur of NK-mediated lysis

artículo científico publicado en 2015

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study

artículo científico publicado en 2017

High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting

artículo científico publicado en 2015

How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma

artículo científico publicado en 2017

How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma

artículo científico publicado en 2010

Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma

artículo científico publicado en 2016

Hypoxia promotes tumor growth in linking angiogenesis to immune escape

artículo científico publicado en 2012

ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease

artículo científico publicado en 2011

ITPR1 protects renal cancer cells against natural killer cells by inducing autophagy

artículo científico publicado en 2014

Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma

artículo científico publicado en 2018

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

artículo científico publicado en 2016

Immunotherapy for Renal Cancer: Sequencing and Combinations

artículo científico

Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels

artículo científico publicado en 2002

Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy

artículo científico publicado en 2012

Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials

artículo científico publicado en 2012

Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy

artículo científico publicado en 2016

Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis

artículo científico publicado en 2015

Interest of color Doppler ultrasonography to evaluate a new anti-angiogenic treatment with thalidomide in metastatic renal cell carcinoma

artículo científico publicado en 2004

Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group

artículo científico publicado en 2002

Interleukin-6 as an emerging regulator of renal cell cancer

artículo científico

Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie

artículo científico publicado en 2004

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

artículo científico publicado en 2009

Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center

artículo científico publicado en 2014

Kidney tumors

artículo científico publicado en 2007

Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials.

artículo científico

Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

artículo científico publicado en 2015

Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma

artículo científico publicado en 2015

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.

artículo científico publicado en 2018

Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.

artículo científico publicado en 2010

MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array

artículo científico publicado en 2014

Malignant effusions and immunogenic tumour-derived exosomes

artículo científico publicado en 2002

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.

artículo científico publicado en 2015

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

artículo científico publicado en 2007

Metabolism of kidney cancer: from the lab to clinical practice

artículo científico publicado en 2013

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study ⬇️

artículo científico publicado en 2017

Metastatic kidney cancer: new therapeutic approaches

artículo científico publicado en 2002

Metastatic renal cell carcinoma management

artículo científico publicado en 2009

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma

artículo científico publicado en 2014

Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies

scientific article published on April 2012

Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives

artículo científico

Nephron-sparing surgery for renal tumors measuring more than 7 cm: morbidity, and functional and oncological outcomes

artículo científico publicado en 2013

New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?

artículo científico publicado en 2017

New therapies after failure of angiogenesis inhibitors

artículo científico publicado en 2009

Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes

artículo científico publicado en 2014

Nivolumab in renal cell carcinoma: latest evidence and clinical potential

artículo científico publicado en 2016

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

artículo científico publicado en 2018

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

artículo científico publicado en 2015

Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?

artículo científico publicado en 2012

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

artículo científico publicado en 2010

Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma

artículo científico publicado en 2011

Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis

artículo científico publicado en 2016

Optimal management of metastatic renal cell carcinoma: current status

artículo científico

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials

artículo científico publicado en 2016

Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon‐α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial ⬇️

artículo científico publicado el 13 de octubre de 2010

Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma

artículo científico publicado en 2005

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

artículo científico publicado en 2005

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

artículo científico publicado en 2010

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors

artículo científico publicado en 2017

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

artículo científico publicado en 2013

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

artículo científico publicado en 2007

Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer

artículo científico publicado en 2014

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

artículo científico publicado en 2009

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer

artículo científico publicado en 2009

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

artículo científico publicado en 2010

Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.

artículo científico publicado en 2005

Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib

artículo científico publicado en 2013

Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours

artículo científico publicado en 2016

Prediction of Progression-Free Survival Rates After Bevacizumab Plus Interferon Versus Interferon Alone in Patients with Metastatic Renal Cell Carcinoma: Comparison of a Nomogram to the Motzer Criteria ⬇️

artículo científico publicado el 21 de diciembre de 2010

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets

artículo científico publicado en 2010

Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer

artículo científico publicado en 2015

Prognosis of renal-cell carcinoma: recognising host genetics

artículo científico publicado en 2012

Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group

artículo científico publicado en 2011

Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study

artículo científico publicado en 2014

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma

artículo científico publicado en 2013

Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?

artículo científico publicado en 2015

Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study

artículo científico publicado en 2007

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor

artículo científico publicado en 2008

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

artículo científico publicado en 2018

Radiotherapy for renal-cell carcinoma

artículo científico

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma ⬇️

artículo científico publicado en 2016

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

artículo científico publicado en 2009

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

artículo científico publicado en 2013

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study

artículo científico publicado en 2014

Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre

artículo científico publicado en 2017

Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with everolimus

artículo científico publicado en 2009

Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status

artículo científico publicado en 2015

Renal cell carcinoma

scientific article published in The Lancet

Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population

artículo científico publicado en 2011

Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzoni's Letter to the Editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and

artículo científico publicado en 2017

Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms

artículo científico

Reversible posterior leukoencephalopathy syndrome induced by axitinib.

artículo científico publicado en 2013

Risk of a Second Kidney Carcinoma Following Childhood Cancer: Role of Chemotherapy and Radiation Dose to Kidneys

artículo científico publicado en 2015

Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report

artículo científico publicado en 2016

Safety of available treatment options for renal cell carcinoma

artículo científico publicado en 2016

Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.

artículo científico publicado en 2013

Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?

artículo científico

Sequencing therapy in metastatic renal cell cancer

artículo científico

Sequential therapy in renal cell carcinoma

artículo científico publicado en 2009

Sequential use of targeted agents in the treatment of renal cell carcinoma

scientific article published on 11 August 2010

Signaling inhibitors in metastatic renal cell carcinoma

artículo científico publicado en 2008

Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies

artículo científico publicado en 2013

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial

artículo científico publicado en 2008

Sorafenib for the management of advanced renal cell carcinoma

artículo científico publicado en 2011

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

artículo científico publicado en 2009

Sorafenib-Sunitinib Sequence: The Jury Is Out.

artículo científico publicado en 2015

Stability of preclinical models of aggressive renal cell carcinomas

artículo científico publicado en 2014

Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?

artículo científico publicado en 2005

Summary of the first annual Genitourinary Medical Oncology Conference Renal Cell Carcinoma Forum

artículo científico publicado en 2007

Sunitinib for the management of advanced renal cell carcinoma

artículo científico publicado en 2010

Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.

artículo científico publicado en 2009

Sunitinib rechallenge in metastatic renal cell carcinoma patients

artículo científico publicado en 2010

Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma

artículo científico publicado en 2016

Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial

artículo científico publicado en 2012

Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis

artículo científico publicado en 2014

Targeted therapies for renal cell carcinoma: review of adverse event management strategies

artículo científico

Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

artículo científico publicado en 2008

Targeting mTOR in cancer: renal cell is just a beginning

scientific article published on 20 June 2010

The autophagy sensor ITPR1 protects renal carcinoma cells from NK-mediated killing

artículo científico publicado en 2015

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer

artículo científico publicado en 2010

The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce

artículo científico publicado en 2008

Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial

artículo científico publicado en 2014

Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors

artículo científico publicado en 2010

Trastuzumab versus lapatinib: the cardiac side of the story

scientific article published on 28 July 2009

Treatment selection in metastatic renal cell carcinoma: expert consensus

artículo científico publicado en 2012

Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data

artículo científico publicado en 2013

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

artículo científico publicado en 2005

Urological cancer: towards rational post-nephrectomy follow-up guidelines in RCC.

artículo científico publicado en 2015

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

artículo científico publicado en 2005

Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib

article

Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma

artículo científico publicado en 2011

Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma

scientific article published on June 2011

[Axitinib in metastatic renal carcinomas: update of knowledge about side effects].

artículo científico publicado en 2014

[Medical therapies for locally advanced/metastatic kidney cancer].

artículo científico publicado en 2014

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda